Are Godavari Drugs latest results good or bad?
Godavari Drugs' latest results are concerning, with a 57.98% decline in Profit After Tax and a 19.4% drop in net sales, marking the lowest quarterly sales in five quarters. While there was a slight profit growth compared to the previous quarter, overall financial health appears weakened.
Godavari Drugs has reported its financial results for the quarter ending March 2025, which reflect several operational challenges. The company's Profit After Tax (PAT) for the latest six months is recorded at Rs 1.66 crore, indicating a notable decline of 57.98% year-on-year. This significant reduction in profitability raises concerns regarding the company's financial health.In terms of sales, Godavari Drugs achieved net sales of Rs 25.50 crore for the quarter, which represents a decline of 19.4% compared to the average net sales of Rs 31.62 crore over the previous four quarters. This figure marks the lowest quarterly sales recorded by the company in the last five quarters, suggesting a persistent negative trend in sales performance.
The quarterly results show a net sales decline of 13.71% compared to the previous quarter, contrasting with a growth of 13.26% in December 2024. However, the standalone net profit for the quarter reflects a growth of 15.58% compared to the previous quarter, which had a decline of 29.36%.
Additionally, the operating profit margin (excluding other income) has shown a slight change, moving from 12.20% in December 2024 to 8.70% in the latest quarter, indicating a decrease in operational efficiency.
Overall, the company has experienced an adjustment in its evaluation, reflecting the challenges it faces in the current market environment.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
